ACIU News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AC

Mkt Cap

$237.4M

Volume

123.19K

Next Earnings

November 3rd

Loading chart

AC

ACIUAC Immune SA

ACIU

Pay with—

Available Balance0.00

AC

Mkt Cap

$237.6M

Volume

123.19K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

PCRX Expands Exparel Commercial Reach in Europe Through Molteni DealPacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201.Zacks Investment Research · Oct 6, 2026

Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa StudyMerck announced that its investigational drug tulisokibart met the primary endpoint in a phase IIb study for moderate to severe hidradenitis suppurativa. High-dose and medium-dose regimens demonstrated superiority over placebo, with 72% and 64% of patients achieving HiSCR50 response respectively, compared to 35% for placebo. The drug also showed improvements in quality of life measures. Merck plans to advance tulisokibart into phase III development for HS and is evaluating it across six immune-mediated indications.Zacks Investment Research · Oct 1, 2026

uniQure Plunges on Additional Data From Huntington's Disease StudyuniQure (QURE) announced mixed phase I/II data for its investigational gene therapy ifezuntirgene inilparvovec for Huntington's disease treatment. At 36 months, the therapy showed 80% slowing in cUHDRS and 67% in TFC versus external controls. However, 48-month data showed weaker results with cUHDRS at 44% slowing (not statistically significant) and TFC at 61% slowing. The stock plunged 37% following the announcement. The company has submitted a BLA to the FDA based on 36-month data, with regulatory review and durability validation as key upcoming catalysts.Zacks Investment Research · Sep 30, 2026

IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026Iovance Biotherapeutics raised its 2026 revenue outlook to $410-$420 million from $350-$370 million, driven by strong patient demand for its therapies Amtagvi and Proleukin. The stock surged 31.5% following the announcement. Amtagvi, the first FDA-approved TIL therapy for melanoma, generated $151 million in sales in H1 2026 with 54% year-over-year growth, and the company plans to expand authorized treatment centers from 100 to at least 110 by year-end.Zacks Investment Research · Sep 30, 2026

Here's Why You Should Add URGN Stock to Your Portfolio NowUroGen Pharma is transitioning from development-stage to commercial-growth biotech, driven by strong Zusduri uptake (73% sequential revenue growth to $50.4M in Q2 2026) and stable Jelmyto sales ($22M in Q2). The company's pipeline includes promising candidates like UGN-103 (94.5% response rate with NDA submitted) and UGN-104, with potential to expand beyond urothelial cancers through a strategic collaboration with IntraGel.Zacks Investment Research · Sep 30, 2026

Best Momentum Stock to Buy for September 30thZacks highlights two stocks with Strong Buy ratings and positive momentum: Stepan Company (SCL), a specialty chemicals manufacturer with a 10.3% earnings estimate increase over 60 days and 12.3% three-month gains; and AC Immune (ACIU), a biopharmaceutical company focused on neurodegenerative diseases with a 28.6% earnings estimate increase and 9.2% three-month gains.Zacks Investment Research · Sep 30, 2026

AbbVie Wins FDA Nod for New Parkinson's Disease Drug JuvmoAbbVie announced FDA approval of Juvmo (tavapadon), a once-daily oral dopamine receptor agonist for Parkinson's disease treatment. The drug can be used alone or with levodopa and represents the first dopaminergic breakthrough for PD in decades. AbbVie expects Juvmo, along with Vyalev and Duopa, to generate over $5 billion in peak sales, strengthening its neuroscience franchise.Zacks Investment Research · Sep 29, 2026

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041Acadia Pharmaceuticals received a Notice of Allowance from the USPTO that extends patent protection for trofinetide (Daybue) to March 2041, adding nearly five years to existing coverage. Daybue sales grew 25% to $226 million in H1 2026, and the drug received EU approval in August 2026, becoming the first and only approved treatment for Rett syndrome in Europe.Zacks Investment Research · Sep 29, 2026

Vertex Posts Positive Phase II Data on Kidney Disease DrugVertex Pharmaceuticals reported positive results from its phase IIb AMPLIFIED study, showing that inaxaplin reduced UACR by 42.7% in AMKD patients with modest proteinuria and 17.3% in those with AMKD and type II diabetes. The company has completed enrollment in the phase II/III AMPLITUDE pivotal study, with interim data expected in early 2027. Inaxaplin was well-tolerated with no serious adverse events reported.Zacks Investment Research · Sep 23, 2026

FDA Accepts Insmed's Filing Seeking Label Expansion for ArikayceInsmed announced FDA acceptance of a regulatory filing for Arikayce label expansion to treat newly diagnosed MAC lung disease patients. The FDA granted priority review with a decision expected by January 28, 2027. Arikayce sales grew 7% to $214.4 million in H1 2026, with full-year expectations of $450-470 million. The label expansion could significantly increase the addressable market from 30,000 to over 200,000 patients.Zacks Investment Research · Sep 22, 2026

to start trading

AC

ACIUAC Immune SA

ACIU

Pay with—

Available Balance0.00

Your PositionYou don't own any ACIU yet.

Related Tickers

Earnings